LifeStance Health Group (NASDAQ:LFST) Stock Rating Upgraded by Barclays

LifeStance Health Group (NASDAQ:LFST) was upgraded by investment analysts at Barclays to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Several other brokerages also recently weighed in on LFST. BTIG Research increased their target price on LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. BMO Capital Markets assumed coverage on shares of LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective on the stock. UBS Group boosted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday. Finally, Wall Street Zen lowered shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.86.

LifeStance Health Group Stock Performance

NASDAQ:LFST traded up $0.03 during midday trading on Monday, reaching $6.51. The stock had a trading volume of 144,831 shares, compared to its average volume of 1,980,247. The stock has a market capitalization of $2.53 billion, a P/E ratio of -216.83 and a beta of 1.13. LifeStance Health Group has a 1-year low of $3.74 and a 1-year high of $8.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. The firm’s fifty day simple moving average is $5.76 and its 200-day simple moving average is $5.31.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm had revenue of $363.81 million during the quarter, compared to analyst estimates of $355.06 million. During the same quarter in the previous year, the business earned ($0.02) EPS. The business’s revenue was up 16.3% on a year-over-year basis. On average, equities research analysts forecast that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

Insider Transactions at LifeStance Health Group

In other news, insider Lisa K. Miller sold 57,240 shares of the stock in a transaction on Friday, November 21st. The shares were sold at an average price of $6.43, for a total value of $368,053.20. Following the completion of the transaction, the insider owned 261,292 shares in the company, valued at approximately $1,680,107.56. This represents a 17.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.60% of the stock is owned by company insiders.

Institutional Trading of LifeStance Health Group

Institutional investors have recently made changes to their positions in the business. US Bancorp DE raised its position in LifeStance Health Group by 1,644.7% in the first quarter. US Bancorp DE now owns 31,718 shares of the company’s stock worth $211,000 after purchasing an additional 29,900 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of LifeStance Health Group by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 11,221,237 shares of the company’s stock valued at $74,733,000 after purchasing an additional 531,841 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of LifeStance Health Group by 4.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,162,136 shares of the company’s stock worth $7,740,000 after buying an additional 48,637 shares in the last quarter. Invesco Ltd. raised its holdings in shares of LifeStance Health Group by 1.4% in the 1st quarter. Invesco Ltd. now owns 164,384 shares of the company’s stock worth $1,095,000 after buying an additional 2,238 shares in the last quarter. Finally, Entropy Technologies LP lifted its position in shares of LifeStance Health Group by 112.8% during the 1st quarter. Entropy Technologies LP now owns 43,389 shares of the company’s stock worth $289,000 after buying an additional 22,998 shares during the period. 85.50% of the stock is currently owned by institutional investors and hedge funds.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.